Why AI for Epilepsy Stays Stuck in the Lab: Landmark Review Maps the Translational Gap

Artificial intelligence has promised a revolution in epilepsy care for more than a decade, with algorithms that can detect seizures in real time, spot the telltale signatures of the disease in brain recordings, and even forecast seizure risk hours before it strikes. Yet walk into most epilepsy clinics today and you will find neurologists relying on the same tools they used before the deep learning boom. A new systematic review, published in Neural Computing and Applications, has now dissected exactly why this disconnect persists, analysing 310 studies published between 2015 and 2025 to expose the structural reasons why so few AI models make it from the benchmark to the bedside.

The research team, led by Yman Chemlal of Hassan II University in Casablanca together with colleagues spanning computer science laboratories and the neurology department of the Mohammed VI University Hospital Center in Tangier, Morocco, applied PRISMA guidelines to select and analyse a decade of literature. Rather than simply cataloguing complaints about AI in epilepsy, as earlier reviews had done, the team took a quantitative approach. They examined how research is actually conducted across four clinical applications: seizure detection, seizure prediction, diagnosis, and treatment support. For each study they recorded the datasets used for training and testing, the data modalities involved, the model architectures chosen, and the evaluation metrics reported. They then compared these observations with the obstacles most frequently cited in the literature, searching for the true root causes of what researchers call the translational gap.

The diagnosis that emerged is stark. The authors identified five interconnected issues that together explain why AI in epilepsy remains largely confined to research papers. The first is a heavy reliance on public datasets, which the review found fail to capture the complexity, noise, and multimodal character of real-world clinical data. Publicly available electroencephalography collections are typically curated, relatively clean, and recorded under controlled conditions. Genuine clinical EEG, by contrast, is riddled with muscle artefacts, electrode faults, patient movement, and the sheer variability of dozens of different recording devices and protocols across hospitals. A model that achieves near-perfect accuracy on a benchmark dataset can collapse when confronted with the messy reality of a hospital monitoring unit, a phenomenon well documented in the broader machine learning for healthcare literature.

The second finding is a striking imbalance in what the field chooses to work on. The review found that 84 percent of studies focus on seizure detection and prediction, and these are precisely the applications dominated by public datasets that were primarily designed for identifying seizure events in the first place. The consequence is a self-reinforcing loop: the easiest data to obtain shapes the research questions that get asked, which in turn produces yet more papers on the same narrow set of tasks. Meanwhile, applications with arguably greater clinical value, such as supporting treatment decisions or assisting diagnosis of difficult cases, remain comparatively underexplored, starved of the large, well-annotated datasets that would make them tractable.

Third, the review uncovered a fundamental mismatch in how success is measured. Most research evaluates model performance using technical classification metrics such as accuracy and sensitivity, which together account for 85 percent of all metrics used across the analysed studies. These numbers are meaningful to machine learning engineers but say little about whether a model actually helps a clinician or a patient. A seizure detection algorithm with 99 percent accuracy might still generate so many false alarms that it becomes unusable in a long-term monitoring setting, or it might miss the seizures that matter most clinically. The authors argue that the field needs evaluation frameworks anchored in genuine clinical needs, such as the number of false alarms per day for wearable devices or the effect on treatment outcomes, rather than abstract percentages computed on held-out test data.

The fourth issue concerns the very architectures that have driven AI’s recent success. The emergence of powerful and high-performing models, including convolutional neural networks and elaborate hybrid designs that combine convolutional, recurrent, attention, and graph-based components, has brought impressive benchmark results but also serious interoperability problems and the notorious black box problem. When a deep network flags a segment of EEG as epileptic, it rarely explains why in terms a neurologist can verify. The review’s nuanced conclusion here is that the challenge is not interpretability in the abstract but clinician reluctance rooted in a lack of trust in these models. Explainable AI techniques have been proposed for seizure detection on EEG signals, but unless the explanations align with clinical reasoning and are validated with the clinicians who must act on them, trust will not follow.

Perhaps most importantly, the fifth finding reframes the translational gap not as a single wall but as a set of different barriers depending on where you stand. In seizure detection and prediction, the dominant obstacles are algorithmic: models that do not generalise beyond their training data and metrics that do not reflect deployment conditions. In diagnosis, the bottleneck is data: too few large, diverse, well-labelled datasets to train and validate models that can distinguish epilepsy from its many mimics. In treatment support, the challenge shifts again to deployment: even promising tools for predicting which antiseizure medication will work for a given patient face regulatory, integration, and workflow hurdles that computer science alone cannot solve. Any serious roadmap, the authors contend, must therefore be tailored application by application rather than prescribing one-size-fits-all fixes.

Based on this multidimensional diagnosis, the team proposes a specific roadmap with strategic actions for each clinical application, aiming to align AI development with actual clinical needs. The directions they sketch echo recommendations already gaining traction across medical AI more broadly, including reporting standards such as TRIPOD+AI for clinical prediction models, the CLAIM checklist for AI in medical imaging, and the DECIDE-AI guidelines designed specifically to bridge the development-to-implementation gap. The review also provides what the authors describe as a scientific framework for guiding the next decade of AI research in epilepsy, intended to help researchers, funders, and clinicians prioritise work that is most likely to reach patients.

The stakes are considerable. Epilepsy affects tens of millions of people worldwide, and roughly a third continue to have seizures despite medication. For these patients, reliable seizure forecasting could transform daily life, restoring the ability to drive, work, and live independently. AI-assisted diagnosis could shorten the often years-long delay before a correct diagnosis and appropriate treatment, particularly where access to specialist neurologists is limited. Tools that predict medication response could spare patients years of trial and error with drugs that fail. None of these benefits will materialise, however, if the research community continues to optimise models for benchmarks rather than for clinics.

The review, published on 23 September 2026 as volume 38, article 751 of Neural Computing and Applications, is likely to become a reference point for the field precisely because it replaces anecdote with measurement. By quantifying where the decade’s effort has gone, which datasets and architectures dominate, and which metrics are used to declare success, it gives the epilepsy AI community its clearest picture yet of why the promised revolution has stalled. The message to researchers is uncomfortable but constructive: the bottleneck is no longer model performance on curated data. It is the alignment between what algorithms are trained to do and what patients and clinicians actually need. Closing that gap, the authors argue, will require clinicians and computer scientists to design studies together from the outset, evaluate models against clinical endpoints, and confront the trust problem head on. The next decade of AI in epilepsy will be judged not by leaderboard scores but by whether algorithms finally begin changing outcomes in the clinic.

Subject of Research: Barriers to translating artificial intelligence applications from research into clinical practice in epilepsy

Article Title: The translational gap in AI for epilepsy: a systematic review and recommendations for future research

Article References: Chemlal, Y., Benamri, I., Ferjouchia, H., Ferjouchia, Z., & Rabhi, A. (2026). The translational gap in AI for epilepsy: a systematic review and recommendations for future research. Neural Computing and Applications, 38(18), Article 751. https://doi.org/10.1007/s00521-026-12460-x

Image Credits: AI Generated

DOI: 10.1007/s00521-026-12460-x

Keywords: artificial intelligence, epilepsy, translational gap, systematic review, seizure detection, seizure prediction, electroencephalography, deep learning, clinical deployment, machine learning, neurology, explainable AI